FE200486

Modify Date: 2024-01-23 13:31:26

FE200486 Structure
FE200486 structure
Common Name FE200486
CAS Number 934246-14-7 Molecular Weight 1710.327
Density N/A Boiling Point N/A
Molecular Formula C84H109ClN18O19 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of FE200486


Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research[1].

 Names

Name (4R)-N-{4-[(2S,5S,8R,11R,14R)-2-({(2R)-1-{[(2S)-1-{[(2S)-1-[(2S)-2-{[(2R)-1-Amino-1-oxo-2-propanyl]carbamoyl}-1-pyrrolidinyl]-6-(isopropylamino)-1-oxo-2-hexanyl]amino}-4-methyl-1-oxo-2-pentanyl]amino}-3-[4-(carbamoylamino)phenyl]-1-oxo-2-propanyl}carbamoyl)-11-(4-chlorobenzyl)-5-(hydroxymethyl)-14-(2-naphthylmethyl)-4,7,10,13,16-pentaoxo-8-(3-pyridinylmethyl)-3,6,9,12,15-pentaazaheptadec-1-yl]phenyl}-2,6-dioxohexahydro-4-pyrimidinecarboxamide acetate hydrate (1:1:1) (non-preferred name)

 FE200486 Biological Activity

Description Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research[1].
Related Catalog
In Vitro Degarelix shows only very weak histamine-releasing properties and the lowest capacity for histamine release among the antagonists of LHRH, including Cetrorelix (HY-P0009), Abarelix (HY-13534), and Ganirelix (HY-P1628)[1]. Degarelix (1 nM-10 μM, 0-72 h) reduces cell viability in all prostate cell lines (WPE1-NA22, WPMY-1, BPH-1, VCaP cells), with the exception of the PC-3 cells[2]. Degarelix (10 μM, 0-72 h) exerts a direct effect on prostate cell growth through apoptosis[2]. Cell Viability Assay[2] Cell Line: WPMY-1, WPE1-NA22, BPH-1, LNCaP and VCaP Concentration: 1 nM-10 μM Incubation Time: WPMY-1 cells at 48 and 72h, WPE1-NA22 cells at 72 hours, BPH-1 cells at 48 and 72h, LNCaP cells at 48 and 72h Result: Reduced cell viability in all prostate cell lines, with the exception of the PC-3 cells. Apoptosis Analysis[2] Cell Line: WPE1-NA22, BPH-1, LNCaP and VCaP Concentration: 10 μM Incubation Time: 24, 48 and 72 h Result: Induced a significant increase on caspase 3/7 activation.
In Vivo Degarelix (0-10 μg/kg; s.c.; once) decreases plasma LH levels and plasma testosterone levels in a dose-dependent manner in castrated rats[3]. Degarelix is stable when incubated in microsomes and cryopreserved hepatocytes from animal liver tissue. In rat and dog, most of the degarelix dose is eliminated within 48 h via urine and feces in equal amounts (40–50% in each matrix), whereas in monkey the major route of excretion is fecal (50%) and renal (22%)[4]. Animal Model: Male Sprague-Dawley rats, castrated[3] Dosage: 0.3, 1, 3 and 10 μg/kg or 12.5, 50, and 200 μg/kg Administration: Subcutaneous injection, once Result: Produced a dose-dependent and reversible decrease in plasma LH levels with a minimal effective dose of 3 μg/kg. For the 50 μg/kg and 200 μg/kg doses, t1/2 of absorption values were 4 min and 30 min, Tmax values were 1 h and 5 h, and apparent plasma disappearance t1/2 values were 12 h and 67 h, respectively. Produced a dose-dependent decrease in plasma testosterone levels with a minimal effective dose of 1 μg/kg.
References

[1]. Rick FG, et al. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther. 2013 Apr 16;6:391-402.

[2]. Sakai M, et al. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonistdegarelix on human prostate cell growth. PLoS One. 2015 Mar 26;10(3):e0120670.

[3]. Broqua P, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormoneantagonist: degarelix. J Pharmacol Exp Ther. 2002 Apr;301(1):95-102.

[4]. Sonesson A, et al. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey. Drug Metab Dispos. 2011 Oct;39(10):1895-903.

 Chemical & Physical Properties

Molecular Formula C84H109ClN18O19
Molecular Weight 1710.327
Exact Mass 1708.780518
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.